On May 21, 2026, Eli Lilly announced positive topline results from the TRIUMPH-1 Phase 3 clinical trial — the primary pivotal efficacy and safety study for retatrutide in adults with obesity or overweight without type 2 diabetes. The announcement marks the most significant regulatory milestone for retatrutide to date and substantially strengthens the Phase 3 data package needed for an eventual FDA filing.
TRIUMPH-1 is a randomized, double-blind, placebo-controlled trial enrolling 2,339 participants — more than six times the size of the Phase 2 trial published in the New England Journal of Medicine in 2023. All three active doses of retatrutide (4 mg, 9 mg, and 12 mg) met both the primary endpoint and all key secondary endpoints, confirming that the efficacy signal first observed in Phase 2 is robust, reproducible, and clinically meaningful at scale.
At the 12 mg maintenance dose over 80 weeks, participants lost a mean of 70.3 pounds (28.3% of body weight). In a pre-specified 104-week extension for participants with BMI ≥35, those on 12 mg reached a mean loss of 85.0 pounds (30.3%) — a level of weight reduction historically associated only with bariatric surgery.
The primary endpoint measured percent total body weight loss at 80 weeks. Results across all dose groups were as follows, compared to placebo:
| Dose | Mean Weight Loss (%) | Mean Weight Loss (lbs) |
|---|---|---|
| 4 mg | 19.0% | 47.2 lbs |
| 9 mg | 25.9% | 64.4 lbs |
| 12 mg | 28.3% | 70.3 lbs |
| Placebo | 2.2% | 5.5 lbs |
The clear dose-response relationship — 19.0%, 25.9%, and 28.3% at the three active doses — is consistent with what was observed in Phase 2 and reinforces the mechanistic rationale for GIP, GLP-1, and glucagon receptor co-agonism. The magnitude of effect at 12 mg surpasses every previously approved obesity medication and every prior Phase 3 obesity trial except TRIUMPH-4 (28.7% at 68 weeks), which enrolled a different population under a different protocol.
In a pre-specified extension sub-study enrolling 532 participants with BMI ≥35, treatment was extended to 104 weeks using a maximum-tolerated dose (MTD) escalation approach. This means participants who had been on a fixed maintenance dose were escalated further if they could tolerate it. Results at 104 weeks:
| Starting Dose → MTD | Weight Loss at 104 Weeks (%) | Weight Loss at 104 Weeks (lbs) |
|---|---|---|
| 4 mg → MTD | 27.9% | 73.3 lbs |
| 9 mg → MTD | 29.5% | 80.7 lbs |
| 12 mg → MTD | 30.3% | 85.0 lbs |
The 30.3% figure at 104 weeks is the headline number because it represents the upper bound of what retatrutide can achieve with extended treatment and optimal dose escalation in a high-BMI population. For a 280-pound patient, 30.3% translates to approximately 85 lbs — an outcome that places retatrutide firmly within the range of surgical weight loss, delivered via a weekly subcutaneous injection.
Beyond mean weight loss, the responder analysis from TRIUMPH-1 provides a more complete picture of the patient-level impact. At the 12 mg dose:
These responder rates are clinically significant. They suggest that for nearly half of patients on the 12 mg dose, retatrutide does not just reduce weight meaningfully — it produces outcomes in the range of what has only been achievable through surgery. The 65.3% BMI <30 responder rate is particularly notable for patients whose primary clinical goal is remission from obesity as defined by BMI classification.
All key secondary endpoints were met across all three active doses. In addition to waist circumference reduction and responder analyses, TRIUMPH-1 demonstrated statistically significant improvements in a panel of cardiometabolic risk markers:
These outcomes extend retatrutide's clinical value beyond weight loss. The simultaneous improvements in lipids, blood pressure, and inflammatory markers suggest that retatrutide addresses the full cardiometabolic cluster that accompanies obesity — not merely the number on the scale. For patients with hypertension, dyslipidemia, or elevated cardiovascular risk, this profile may carry independent clinical weight in future prescribing decisions.
The safety profile observed in TRIUMPH-1 is consistent with what was reported in Phase 2 and in TRIUMPH-4. The most common adverse events are gastrointestinal and dose-dependent:
| Adverse Event | Incidence (across active doses) |
|---|---|
| Nausea | 28.6% – 42.4% |
| Diarrhea | 25.2% – 34.1% |
| Constipation | 23.8% – 26.1% |
| Vomiting | 10.6% – 25.3% |
Discontinuation rates due to adverse events ranged from 4.1% to 11.3% across active dose groups, compared to 4.9% in the placebo group. Notably, the discontinuation rate in TRIUMPH-1 is substantially lower than the 18.2% observed at 12 mg in TRIUMPH-4, which used a more aggressive titration schedule. This difference likely reflects protocol refinements applied in TRIUMPH-1's titration design. Full safety data, including dysesthesia rates and serious adverse events, are expected in the peer-reviewed publication.
TRIUMPH-1 is the larger, longer, primary pivotal study. TRIUMPH-4 (December 2025) was a 68-week study with a more aggressive titration and a somewhat different protocol. Both are Phase 3 data — and taken together, they form the core of the efficacy case Lilly will present to the FDA.
| Parameter | Phase 2 (48 wk) | TRIUMPH-4 (68 wk) | TRIUMPH-1 (80 wk) |
|---|---|---|---|
| Sample size | 338 | ~800 | 2,339 |
| 12 mg mean weight loss | ~24.2% | 28.7% | 28.3% |
| All doses met endpoints | Yes | Yes | Yes |
| Discontinuation (12 mg) | Not comparable | 18.2% | 11.3% (max) |
The consistency of the 28%+ weight loss figure across two independent Phase 3 trials with different designs and durations is a powerful regulatory signal. It demonstrates that the efficacy outcome is not an artifact of a particular protocol but a reproducible property of the molecule itself.
TRIUMPH-1 covers adults with obesity and overweight without type 2 diabetes. Two additional major readouts remain:
Eli Lilly has not announced a specific NDA submission date as of May 2026. Based on standard FDA regulatory timelines, an NDA filing could plausibly occur in late 2026 or early 2027 once the Phase 3 data package is complete and the peer-reviewed publications are in order. For a detailed analysis of the regulatory pathway, see the dedicated retatrutide FDA approval timeline article.
TRIUMPH-1 does not change the fundamental regulatory math — an NDA still requires completing and filing the full Phase 3 package — but it significantly de-risks the efficacy case. The FDA now has two independently-powered Phase 3 studies in the same population demonstrating weight loss in excess of 28% at the 12 mg dose. That is an unusually strong foundation for an obesity drug NDA.
Join the waitlist for priority access to a prescribing physician when retatrutide receives FDA approval.
Join the WaitlistThis article is for educational purposes only and does not constitute medical advice. Retatrutide is an investigational drug and is not FDA approved as of publication. Clinical data referenced is from Eli Lilly's May 21, 2026 press release and related topline announcements. Peer-reviewed publication of TRIUMPH-1 results is pending. Consult a qualified healthcare provider before making any treatment decisions.